GLP-1 NAION Lawsuit: Vision Loss & Blindness Claims
The GLP-1 NAION Lawsuit is an active multidistrict litigation. If you or a loved one used a GLP-1 medication like Ozempic or Wegovy and suffered sudden vision loss or were diagnosed with NAION, you may be eligible to seek significant financial compensation.
GLP-1 Lawsuits for Eye Strokes & Blindness
Popular GLP-1 receptor agonists—such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound—have skyrocketed in popularity across the United States for diabetes management and weight loss. While heavily marketed as miracle drugs with manageable side effects, crucial clinical data have emerged linking these medications to a devastating, permanent form of blindness.
Because the injuries, medical experts, and legal criteria surrounding eye damage are completely distinct from the gastrointestinal injuries (like gastroparesis) handled in MDL 3094, the Judicial Panel on Multidistrict Litigation established MDL 3163: In Re: GLP-1 Receptor Agonists NAION Products Liability Litigation.
Centralized in the U.S. District Court for the Eastern District of Pennsylvania under the Honorable Karen Spencer Marston, this specialized docket handles all federal failure-to-warn lawsuits regarding GLP-1 vision loss. Judge Marson also presides over the GLP-1 MDL that focuses on gastrointestinal injuries.
To speak directly with an attorney regarding your vision loss claim, call us at (202) 792-7927.
Major GLP-1 NAION MDL 3163 Updates
March 2026 – Court Sets “Science Day” Guidelines
Judge Karen Marston entered a foundational order outlining the procedural ground rules for an upcoming MDL Science Day. Science Days are a critical phase in pharmaceutical litigation where either the attorneys or expert physicians, neuro-ophthalmologists, and scientists present objective, non-adversarial educational lectures to the court. This science day will focus on how GLP-1 drugs interact with ocular blood flow and the diagnostic criteria for NAION.
Late 2025 – Centralization of NAION Claims Into MDL 3163
Recognizing that hundreds of unique vision impairment lawsuits were being filed nationwide, the JPML officially established MDL 3163. The panel noted that while the primary GLP-1 litigation (MDL 3094) moves forward with stomach-paralysis claims, the scientific mechanisms, unique medical terminology, and specific warning labels required for blindness claims warranted an independent, dedicated management track.
The Science: How Ozempic & Wegovy Are Linked to Blindness
On July 3, 2024, a landmark study published by researchers at Mass Eye & Ear (Harvard Medical School) uncovered a shocking correlation between semaglutide use and a rare ocular condition known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
What is NAION?
Often referred to as an “eye stroke,” NAION occurs when the critical blood supply flowing to the optic nerve head is suddenly blocked or restricted. This lack of oxygen damages the nerve permanently, resulting in sudden, painless, and typically irreversible vision loss in one eye. It stands as the second-leading cause of optic nerve blindness worldwide, trailing only glaucoma. While NAION typically only impacts one eye, if a patient continues to take a GLP-1 after suffering NAION in one eye, it is possible for the patient to later develop NAION in the other eye too.
Understanding the Expanded Risk Data:
The Mass Eye & Ear study analyzed years of clinical data and discovered that the risk of developing this debilitating form of blindness was profoundly higher for individuals prescribed a form of semaglutide, including Ozempic, Wegovy and Rybelsus:
- For Diabetic Patients: Individuals using Ozempic for Type 2 diabetes were found to be 4 times more likely to be diagnosed with NAION compared to those on non-GLP-1 diabetes therapies.
- For Overweight/Obese Patients: Individuals prescribed Wegovy for weight management saw an even more dramatic spike, measuring 7 times more likely to develop NAION than those using alternative weight-loss treatments.
Nigh Goldenberg Raso & Vaughn has spoken with numerous clients who report experiencing sudden, unprovoked vision impairment—often resembling a dark shadow or blur in the upper or lower half of their visual field—within the first several weeks or months of starting a GLP-1 prescription. If you have experienced similar visual side effects while taking Ozempic or Wegovy, contact NGRV today.
The Legal Issue: A Clear Failure to Warn
Pharmaceutical manufacturers hold a strict legal obligation to warn of all known, severe adverse events associated with their products.
While the warning labels for medications like Ozempic and Wegovy mention general “vision changes” or diabetic retinopathy complications, they completely fail to warn patients or prescribing doctors about the risk of permanent blindness or NAION. Minor vision changes are frequent and unexpected in those with uncontrolled diabetes. A physician reading the Ozempic warning label would have no idea that the patient being prescribed the drug could suddenly go blind as a side effect. Drug manufacturers generated billions of dollars in revenue while keeping patients completely in the dark regarding these catastrophic visual side effects. A GLP-1 lawsuit allows victims to seek damages for:
- Past and future medical care (neuro-ophthalmology visits, low-vision therapy).
- Loss of quality of life and independence due to permanent blindness.
- Lost wages or reduced earning capacity.
- Pain, suffering, and mental anguish.
Meet Our GLP-1 Litigation Attorneys
The dedicated pharmaceutical litigation team at our firm brings decades of combined experience confronting multinational drug corporations. We understand the complex medical arguments required to prove pharmaceutical failure-to-warn claims and are actively investigating GLP-1 NAION eye stroke cases nationwide.
If you or a loved one suffered severe visual impairment after taking a GLP-1 medication, you are not alone. We handle all cases on a contingency-fee basis, meaning there are absolutely no upfront fees or out-of-pocket legal expenses unless we successfully recover money for your claim.
Contact Us for a Free Case Evaluation
- Phone: (202) 792-7927
- Email: Intake@nighgoldenberg.com
- Available: Monday–Friday, 8:00 a.m. – 5:00 p.m.
